Blagov Alexander V, Orekhova Varvara A, Sukhorukov Vasily N, Melnichenko Alexandra A, Orekhov Alexander N
Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, Moscow 125315, Russia.
Institute for Atherosclerosis Research, Osennyaya Street 4-1-207, Moscow 121609, Russia.
Pharmaceuticals (Basel). 2023 Aug 14;16(8):1150. doi: 10.3390/ph16081150.
Since inflammatory bowel diseases (IBDs) are chronic, the development of new effective therapeutics to combat them does not lose relevance. Oxidative stress is one of the main pathological processes that determines the progression of IBD. In this regard, antioxidant therapy seems to be a promising approach. The role of oxidative stress in the development and progression of IBD is considered in detail in this review. The main cause of oxidative stress in IBD is an inadequate response of leukocytes to dysbiosis and food components in the intestine. Passage of immune cells through the intestinal barrier leads to increased ROS concentration and the pathological consequences of exposure to oxidative stress based on the development of inflammation and impaired intestinal permeability. To combat oxidative stress in IBD, several promising natural (curcumin, resveratrol, quercetin, and melatonin) and artificial antioxidants (N-acetylcysteine (NAC) and artificial superoxide dismutase (aSOD)) that had been shown to be effective in a number of clinical trials have been proposed. Their mechanisms of action on pathological events in IBD and clinical manifestations from their impact have been determined. The prospects for the use of other antioxidants that have not yet been tested in the treatment of IBD, but have the properties of potential therapeutic candidates, have been also considered.
由于炎症性肠病(IBD)是慢性疾病,开发新的有效治疗方法来对抗它们仍然具有重要意义。氧化应激是决定IBD进展的主要病理过程之一。在这方面,抗氧化治疗似乎是一种有前景的方法。本综述详细探讨了氧化应激在IBD发生发展中的作用。IBD中氧化应激的主要原因是白细胞对肠道微生物群失调和食物成分反应不足。免疫细胞穿过肠道屏障会导致活性氧(ROS)浓度升高,并基于炎症发展和肠道通透性受损而产生氧化应激暴露的病理后果。为了对抗IBD中的氧化应激,已经提出了几种有前景的天然抗氧化剂(姜黄素、白藜芦醇、槲皮素和褪黑素)和人工抗氧化剂(N-乙酰半胱氨酸(NAC)和人工超氧化物歧化酶(aSOD)),它们在一些临床试验中已被证明是有效的。已经确定了它们对IBD病理事件的作用机制以及由此产生的临床表现。还考虑了其他尚未在IBD治疗中进行测试但具有潜在治疗候选特性的抗氧化剂的应用前景。